Old drug, new hope: mercaptopurine tested against rare cancer syndrome
NCT ID NCT07716735
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney cancers or other growths. Participants must have a specific gene mutation and be in good overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mercaptopurine, a chemotherapy drug that stops cancer cell growth
- What this could lead to
- If it works, this could offer a treatment option for people with HLRCC, a rare genetic condition that raises the risk of kidney cancer and other tumors.
- What could go wrong
- This is an early-phase trial with only 18 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KIDNEY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
- Radiation boosts immunotherapy in kidney cancer trial
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?
- Immunotherapy duo shows promise in kidney cancer battle